The Latest Clinical Advances in Thrombocytopenia

© 2022 by the authors; CC BY-NC-ND license

thrombotic thrombocytopenic purpura; depression; resilience; quality of life; inherited thrombocytopenias; platelets; bleeding; thrombotic thrombocytopenic purpura; TTP; ADAMTS13; treatment; diagnosis; follow-up; review; caplacizumab; pseudothrombocytopenia; platelets; hematimetry; fluorescence; amikacin; anticoagulants; COVID-19; platelet; thrombocytopenia; cardiac surgery; inflammation; biological prosthesis; extracorporeal life support; heparin-induced thrombocytopenia (HIT); new concepts; pathogenesis; diagnosis; management; immune PF4/heparin/antibody complexes; Bayesian diagnostic thinking; therapeutic plasma exchange; intravenous immunoglobulins (IVIG); immune thrombocytopenia; bleeding; platelets; platelet destruction; immune tolerance; megakaryocytes; ITP treatment; virus infection; thrombocytopenia; thrombocytopathy; aggregation; HIV; SARS-CoV-2; hantavirus; coronavirus; influenza; thrombocytopathy; platelet disorders; procoagulant platelets; activation endpoints; thrombocytopenia; myelodysplastic syndromes (MDS); bone marrow failure (BMF) syndromes; aplastic anemia (AA); next-generation sequencing (NGS); thrombocytopenia; bleeding; platelet function tests; platelet disorders; platelet count; flow cytometry; anticoagulation; antifibrinolytic; antiplatelet; cancer; thrombocytopenia; thrombopoietin receptor agonist; tranexamic acid; advanced liver disease; bleeding risk; cirrhosis; hemostasis; thrombocytopenia; thrombopoietin receptor agonists/mimetics; platelet transfusion guidelines; platelet transfusion alternatives; platelet additive solutions; platelet pathogen inactivation/reduction; cold stored platelet concentrates; n/a